HUTCHMED (China) Limited (HK:0013) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HUTCHMED (China) Limited has appointed Cavendish Capital Markets Limited as a joint corporate broker in London, effective January 1, 2025. This move, alongside continuing partnerships with Panmure Liberum Limited and HSBC Bank plc, reflects HUTCHMED’s strategic efforts to strengthen its financial market presence. The biopharmaceutical company focuses on developing and commercializing therapies for cancer and immunological diseases.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.